Taysha Gene Therapies, Inc.
TSHA
$6.85
$0.030.44%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
Insider Monkey
5/12/2026
-
Tickeron - Stocks
5/11/2026
-
Insider Monkey
5/11/2026
-
Simply Wall St
5/11/2026
-
TipRanks Financial Blog
5/10/2026
-
TipRanks Financial Blog
5/10/2026
-
MarketBeat
5/9/2026
-
MarketBeat
5/6/2026
-
The Cerbat Gem
5/6/2026
-
MarketBeat
5/6/2026
-
TipRanks Financial Blog
5/6/2026
-
TipRanks Financial Blog
Taysha Gene Therapies (TSHA, $6.94) price may drop as it broke higher Bollinger Band on May 05, 2026
5/6/2026
-
Tickeron - Stocks
5/6/2026
-
Tickeron - Stocks
5/6/2026
-
Globe Newswire
5/5/2026
-
MarketBeat
5/5/2026
-
SeekingAlpha.com: All News
5/2/2026
-
Tickeron - Stocks
5/2/2026
-
MarketBeat
5/1/2026
-
Globe Newswire
4/29/2026
-
Globe Newswire
4/28/2026
-
Simply Wall St
4/27/2026
-
Globe Newswire
4/26/2026
-
Simply Wall St
4/24/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 6, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
214 612 0000
Address
3000 Pegasus Park Drive
Dallas, TX 75247
Dallas, TX 75247
Country
Year Founded
Business Description
Sector
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic...
more